Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nature Medicine
Robichaux, Jacqulyne P JP; Elamin, Yasir Y YY; Tan, Zhi Z; Carter, Brett W BW; Zhang, Shuxing S; Liu, Shengwu S; Li, Shuai S; Chen, Ting T; Poteete, Alissa A; Estrada-Bernal, Adriana A; Le, Anh T AT; Truini, Anna A; Nilsson, Monique B MB; Sun, Huiying H; Roarty, Emily E; Goldberg, Sarah B SB; Brahmer, Julie R JR; Altan, Mehmet M; Lu, Charles C; Papadimitrakopoulou, Vassiliki V; Politi, Katerina K; Doebele, Robert C RC; Wong, Kwok-Kin KK; Heymach, John V JV